Comparison · NCT02514824-sae
Dose Level 1: MLN01283 3 mg (Phase 1) vs Dose Level 2: MLN01283 4 mg (Phase 1): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dose Level 1: MLN01283 3 mg (Phase 1) vs Dose Level 2: MLN01283 4 mg (Phase 1): serious adverse events. Trial comparisons, record NCT02514824-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02514824-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.49 | wilson | |
| Risk in group 2 | 0.6 | 0.231 | 0.882 | wilson | |
| Risk difference, group 1 minus group 2 | -0.6 | -0.882 | 0.0135 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with a serious adverse event on Dose Level 1: MLN01283 3 mg (Phase 1) than on Dose Level 2: MLN01283 4 mg (Phase 1) | 1.67 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dose Level 1: MLN01283 3 mg (Phase 1) | Phase 1 dose level 1 participants receive MLN01283 3mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons. | 0 | 4 | EG000 |
| Group 2 | Dose Level 2: MLN01283 4 mg (Phase 1) | Phase 1 dose level 2 participants receive MLN01283 4 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons. | 3 | 5 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Assessed on treatment and for this study cohort the longest treatment duration was approximately 4 months in each dose level 1 and 2.
Source ClinicalTrials.gov
Trial
- Title
- MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
- NCT number
- NCT02514824
- Phases
- PHASE1, PHASE2
- Conditions
- Merkel Cell Carcinoma
- Interventions
- MLN0128
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2020-12-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02514824?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02514824-sae